

Comparability and Compatibility Studies of TBI-2001: a Novel CAR T Cell Product with a JAK/STAT Signaling Domain.

Nguyen, L¹, Dojo Soeandy, C¹, Fisher, K¹, Fyrsta, M¹, Le, M¹, Lo, C¹, Murakami, K¹, Nie J¹, Scheid E¹, Saso, K¹, Ohashi, P^{1,2}, Nakanishi, R³, Nomura, K³, Tanaka, M³, Butler, M^{1,2,4}, Hirano, N^{1,2};
¹Tumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA, ²Department of Immunology, University of Toronto, Toronto, ON, CANADA, ³Takara Bio, Inc., Shiga, JAPAN, ⁴Department of Medicine, University of Toronto, Toronto, ON, CANADA.

BACKGROUND

A phase I/Ib clinical trial has been developed for a first-in-human Chimeric Antigen Receptor (CAR) T cell product called "TBI-2001".

TBI-2001 recognizes CD19 and expresses a signaling domain that leads to the activation of JAK/STAT pathways. The CAR construct has shown enhanced antitumor activity in preclinical studies (Kagoya et al., Nat Med. 2018).


The trial is a single-centre study at the Princess Margaret Cancer Centre (PMCC) in Toronto.

Manufacturing of TBI-2001 is performed at the point of care. The manufacturing process was developed by Takara Bio Inc; technology transfer was performed from Takara to the PMCC. Subsequent preclinical studies included comparability and compatibility studies which were performed by Takara and the PMCC.

Kagoya Y, et al., Nature Medicine 2018, 24(3), 352-359


A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects

Yuki Kagoya¹, Shinya Tanaka^{1,2}, Tingxi Guo^{1,3,4}, Mark Anczurovski^{1,3}, Chung-Hsi Wang^{1,3}, Kayoko Saso¹, Marcus O Butler^{1,3,4}, Mark D Minden⁵ & Naoto Hirano^{1,2,3}




Structure of the novel CAR in TBI-2001. The CAR is composed of a CD19-specific scFv antigen recognition domain, a CD28 transmembrane domain, and intracellular domains derived from CD28, IL-2 receptor beta (IL-2RB), and CD3z, with a STAT-3 binding YXXQ motif.

NALM-6-Luc (high tumor burden) in NSG mice




Primary B-ALL in NSG mice




JAK-STAT CD19 CAR-T cells have superior antitumor effects in vivo. T cells expressing previous-generation or novel CARs were adoptively transferred into mice bearing NALM-6 tumor cells (top graphs) or primary B-ALL cells (bottom graphs). Tumor burden and overall or event free survival were assessed.

PREPARATION FOR CLINICAL TRIAL WITH POINT-OF-CARE MANUFACTURING



OVERVIEW OF MANUFACTURING



Autologous peripheral lymphocytes are isolated from an apheresis product. Lymphocytes are activated with RetroNectin[®] and anti-CD3 mAb (OKT3). Prior to the transduction procedure, retrovirus particles are pre-loaded in RetroNectin[®]-coated bags at 4°C (Katsuyuki Dodo, et al., PLoS ONE 9(1): e86275). The activated lymphocytes are then seeded in the pre-loaded bags. After the transduction procedure, the lymphocytes are expanded, followed by cell harvest, final formulation and cryopreservation.

COMPARABILITY STUDY

Purpose: The scope of the Comparability Study was to assess data from TBI-2001 full-scale validation batches manufactured at the PMCC against data from test batches manufactured at Takara. The purpose of this assessment was to confirm that the controlled process used for the manufacture of TBI-2001 minimizes variability such that data from pre-clinical studies and stability studies generated using Takara's batches are relevant to the PMCC's Clinical Trial Application (CTA).

Approach:

1. Comparability Assessment Based on Batch Characteristics

Batch manufacturing data and quality testing data were evaluated as follows:

- Release tests with defined acceptance criteria, e.g. identity, purity, potency, safety.
- Additional characterization tests with defined acceptance criteria.
- In-process control tests assessed qualitatively for comparability.

2. Comparability Assessment Based on Stress Testing

Degradation of the final product under stress conditions was evaluated as follows:

- Final Product was subjected to stress conditions.
- Product degradation was assessed over time.
- Results were assessed against predefined numerical acceptance criteria.
- The overall rate of degradation was also assessed qualitatively.


Results:

1. Comparability Assessment Based on Batch Characteristics

- All product specification test results from the batches manufactured at the PMCC met the target ranges as established by the Takara batches.
- All results from the additional characterization tests also met the target ranges.

2. Comparability Assessment Based on Stress Testing

- Stress induced degradation of TBI-2001 validation batches manufactured at the PMCC and at Takara met acceptance criteria for comparability.



Degradation of TBI-2001 under stress conditions was comparable for validation batches manufactured at the PMCC and Takara. TBI-2001 final products from validation batches were subjected to stress conditions and assessed for degradation over time.

Conclusion:


Validation batches manufactured at the PMCC were comparable to the validation batches manufactured at Takara.

COMPATABILITY STUDY

Purpose:

The purpose of the Compatibility Study was to assess the suitability of administration materials for the infusion of TBI-2001.

Approach:



- Two final product concentrations were tested in duplicate.
- Examples of administration materials: non-filtered administration sets, peripherally inserted central catheter (PICC), tubing, port connectors and adaptors.
- Maximum allowable hold-time prior to infusion was tested.
- Readouts: pre-infusion and post-infusion samples assayed for four relevant release tests.
- Acceptance criteria for compatibility: post-infusion cells meet final product specifications for batch release.
- Assessment of cell recovery (yield) was also performed.
- Qualitative comparison of results from pre- and post-infusion samples was performed.

Results:

- All acceptance criteria were met.
- Cell recovery (yield) was high.
- Assay results from pre- versus post-infusion samples showed nominal changes of < 2%.

Conclusion:

The data from this Compatibility Study supported the use of the administration materials for TBI-2001.

CLINICAL TRIAL: OPEN TO ACCRUAL

| | |
|------------------------------|---|
| ClinicalTrials.gov ID | NCT05963217 |
| Sponsor | Princess Margaret Cancer Centre, University Health Network |
| Title | Phase I/Ib Study of TBI-2001 for Patients with Relapsed or Refractory CD19+ B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) |
| Study site | Princess Margaret Cancer Centre, Canada (single centre study) |
| TBI-2001 manufacture site | Princess Margaret Cancer Centre, Canada |
| Investigators | PI: Marcus Butler. Co-Is: Christine Chen, John Kuruville, Linh Nguyen |
| Lymphodepleting chemotherapy | IV cyclophosphamide (500 mg/m ² once daily) and IV fludarabine (30 mg/m ² once daily) to be given concurrently for 3 days starting from -10 to -5 days before cell infusion. |
| TBI-2001 Dose | Phase I: Cohort 1: 3 x 10 ⁵ CAR-positive cells/kg Cohort 2: 1 x 10 ⁶ CAR-positive cells/kg Cohort 3: 3 x 10 ⁶ CAR-positive cells/kg (maximum of 2 x 10 ⁸ CAR-positive cells/patient) Phase Ib: RP2D |
| Frequency of Administration | Single dose |
| Planned sample size | 19 – 28 |